Neurogenic

About

Headcount over time

Q&A

What is Neurogenic's primary focus?

Neurogenic is a clinical-stage diagnostics company that develops sensitive immunoassays to aid in the diagnosis of mental disorders.

What specific condition is Neurogenic's current assay designed to detect?

Neurogenic's current assay is an ELISA-based immunoassay designed to detect autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients with early-onset symptoms of schizophrenia.

What is the current development stage of Neurogenic's assay?

Neurogenic is in the final stages of assay optimization and is continuing clinical field testing and validation of the assay.

With which institutions has Neurogenic established collaborations?

Neurogenic has long-term collaborations with the Weizmann Institute of Science, Tel Aviv University's Department of Psychiatry, Beer Yaakov-Ness-Ziona Mental Health Center, Geha Mental Health Center, and the Laboratory of Biological Psychiatry at Felsenstein Medical Research Center.

When was Neurogenic founded?

Neurogenic was founded in February 1995.

How many employees does Neurogenic have?

Neurogenic has 1-10 employees.

What is Neurogenic's current funding stage?

Neurogenic is currently in the Pre-Funding stage.

In which sector does Neurogenic primarily operate?

Neurogenic's primary sector is Health Tech & Life Sciences.

Sectors & technology

Highlights

Tags